PAT and Quality by Design exemplified in a Mock P2 ...gmpeye.co.kr/gmpguidesandguidelines/quality by...
-
Upload
phungkhanh -
Category
Documents
-
view
233 -
download
1
Transcript of PAT and Quality by Design exemplified in a Mock P2 ...gmpeye.co.kr/gmpguidesandguidelines/quality by...
![Page 1: PAT and Quality by Design exemplified in a Mock P2 ...gmpeye.co.kr/gmpguidesandguidelines/quality by design... · 3 Introduction EFPIA PAT Topic Group Chris Potter AstraZeneca: Chairman](https://reader030.fdocuments.us/reader030/viewer/2022013107/5b5877407f8b9a655d8c0ad1/html5/thumbnails/1.jpg)
1
PAT and Quality by Design exemplified in a Mock P2 submission for examplain tablets
Part 1: Concept and PrinciplesPart 2: Mock P2 Submission
![Page 2: PAT and Quality by Design exemplified in a Mock P2 ...gmpeye.co.kr/gmpguidesandguidelines/quality by design... · 3 Introduction EFPIA PAT Topic Group Chris Potter AstraZeneca: Chairman](https://reader030.fdocuments.us/reader030/viewer/2022013107/5b5877407f8b9a655d8c0ad1/html5/thumbnails/2.jpg)
2
Part 1 – Concept and Principles
IntroductionRationale ConceptObjectiveMock P2 DocumentPrinciplesExample chosen
![Page 3: PAT and Quality by Design exemplified in a Mock P2 ...gmpeye.co.kr/gmpguidesandguidelines/quality by design... · 3 Introduction EFPIA PAT Topic Group Chris Potter AstraZeneca: Chairman](https://reader030.fdocuments.us/reader030/viewer/2022013107/5b5877407f8b9a655d8c0ad1/html5/thumbnails/3.jpg)
3
IntroductionEFPIA PAT Topic Group
Chris Potter AstraZeneca: ChairmanRafael Beerbohm Boehringer-IngelheimAlastair Coupe PfizerFritz Erni NovartisGerd Fischer Sanofi-AventisStaffan Folestad AstraZenecaGordon Muirhead GSKStephan Roenninger F Hoffmann-La RocheAlistair Swanson Pfizer
![Page 4: PAT and Quality by Design exemplified in a Mock P2 ...gmpeye.co.kr/gmpguidesandguidelines/quality by design... · 3 Introduction EFPIA PAT Topic Group Chris Potter AstraZeneca: Chairman](https://reader030.fdocuments.us/reader030/viewer/2022013107/5b5877407f8b9a655d8c0ad1/html5/thumbnails/4.jpg)
4
IntroductionMock P2 Document
Not a complete P2 Pharmaceutical Development sectionA simplified case to exemplify fundamental principles and key concepts, promoting discussionFocus on regulatory implications of manufacturing concepts of the futureQuality by Design related to the Target Product ProfileDemonstration of Risk Management (RM) applied to pharmaceutical development
![Page 5: PAT and Quality by Design exemplified in a Mock P2 ...gmpeye.co.kr/gmpguidesandguidelines/quality by design... · 3 Introduction EFPIA PAT Topic Group Chris Potter AstraZeneca: Chairman](https://reader030.fdocuments.us/reader030/viewer/2022013107/5b5877407f8b9a655d8c0ad1/html5/thumbnails/5.jpg)
5
RationaleCurrent regulatory hurdles in changing without prior approval:
Analytical or manufacturing processesEquipment, Sites and ScaleOngoing stability programs
Use process understanding to derive real time releaseNeed examples as basis for discussion and clarification of uncertainties within industry and authoritiesUse as an example for future submission documentation (not the only way)Foundation laid for the science based discussion
![Page 6: PAT and Quality by Design exemplified in a Mock P2 ...gmpeye.co.kr/gmpguidesandguidelines/quality by design... · 3 Introduction EFPIA PAT Topic Group Chris Potter AstraZeneca: Chairman](https://reader030.fdocuments.us/reader030/viewer/2022013107/5b5877407f8b9a655d8c0ad1/html5/thumbnails/6.jpg)
6
ConceptAssumptions
Mock P2 Document “Examplain” chosen as a simple product manufactured with a non-complex process but with a critical to quality attribute.New paradigms linked with the application of practical tools and elements, for instance
Risk Management tools, rapid on-line measurements of relevant material attributesContinuous verification to replace traditional process validationModels and prediction
![Page 7: PAT and Quality by Design exemplified in a Mock P2 ...gmpeye.co.kr/gmpguidesandguidelines/quality by design... · 3 Introduction EFPIA PAT Topic Group Chris Potter AstraZeneca: Chairman](https://reader030.fdocuments.us/reader030/viewer/2022013107/5b5877407f8b9a655d8c0ad1/html5/thumbnails/7.jpg)
7
ObjectiveMock P2 Document
Preparation of a draft document paper based on current industry thinking to enable discussion with authorities and within industry for the implementation of Quality by Design (QbD) and PAT principles in future submission papers focused on the current P2 document content
![Page 8: PAT and Quality by Design exemplified in a Mock P2 ...gmpeye.co.kr/gmpguidesandguidelines/quality by design... · 3 Introduction EFPIA PAT Topic Group Chris Potter AstraZeneca: Chairman](https://reader030.fdocuments.us/reader030/viewer/2022013107/5b5877407f8b9a655d8c0ad1/html5/thumbnails/8.jpg)
8
An Industry View of QbD in Dossier: Key Scientific Elements and ‘Flow’
TargetTargetProductProduct
ProfileProfile
ControlControlStrategyStrategy
PriorPriorKnowledgeKnowledge
Product/Product/ProcessProcessDev.Dev.
Product/Product/ProcessProcessDesignDesignSpace Space
Definition of Product Intended Use and pre-definition of Qualitytargets (wrt clinical relevance, efficacy and safety)
Summary of Scientific Understanding of Product andProcess.Justification and description of Multi-dimensional Space that Assures Quality(interrelation-ships and boundaries of Clinical Relevance).
Definition ofControl Strategybased on Design Space leading to Control of Quality and Quality Risk Mgmt.(Process Robustness)
Overview ofQuality by Design key actions and decisions taken to develop New Scientific Knowledge, e.g. DoE, PAT, Risk Assessmentand Risk Control
Summary ofPrior Scientific Knowledge(drug substance, excipients; similar formulations and processes). Initial Risk Assessment
RegulatoryRegulatoryFlexibilityFlexibility
Proposal of Regulatory Flexibility based on Product and Process Scientific Knowledgeand Quality Risk Mgmt.(Materials, Site, Scale etc)
![Page 9: PAT and Quality by Design exemplified in a Mock P2 ...gmpeye.co.kr/gmpguidesandguidelines/quality by design... · 3 Introduction EFPIA PAT Topic Group Chris Potter AstraZeneca: Chairman](https://reader030.fdocuments.us/reader030/viewer/2022013107/5b5877407f8b9a655d8c0ad1/html5/thumbnails/9.jpg)
9
Mock P2 DocumentStructure
Format CTD / P2Type = MockReferences
“Core P2 document only- cross – references to other CTD sections necessary for certain elements (e.g. Method Validation)”
ContentTarget Product Profile linked to patient safety and efficacyRisk Management toolsDesign Space developmentRational for Control Strategy and impact on end product testing
![Page 10: PAT and Quality by Design exemplified in a Mock P2 ...gmpeye.co.kr/gmpguidesandguidelines/quality by design... · 3 Introduction EFPIA PAT Topic Group Chris Potter AstraZeneca: Chairman](https://reader030.fdocuments.us/reader030/viewer/2022013107/5b5877407f8b9a655d8c0ad1/html5/thumbnails/10.jpg)
10
Mock P2 Document Candidate
As candidate a solid oral dosage form BCS class I containing a well characterised drug substance had been chosen
Target Product Profile:
Description Round normal convex uncoated tablet
Identification Positive
Assay 20 mg ± 5% active at time of manufacture
Degradation products Qualified meeting ICH Q3B and Q6A criteria
Dissolution Immediate release
Uniformity of dosage units
Meets pharmacopoeial acceptance criteria
Microbiological limits Meets pharmacopoeial acceptance criteria
![Page 11: PAT and Quality by Design exemplified in a Mock P2 ...gmpeye.co.kr/gmpguidesandguidelines/quality by design... · 3 Introduction EFPIA PAT Topic Group Chris Potter AstraZeneca: Chairman](https://reader030.fdocuments.us/reader030/viewer/2022013107/5b5877407f8b9a655d8c0ad1/html5/thumbnails/11.jpg)
11
“Examplain” TabletsBrief Description
“Examplain” an immediate release solid dosage formTablet of 200 mg containing 20 mg drug substanceBiopharmaceutics Class I (highly soluble, highly permeable)Conventional, wet granulated tablet formulationSome potential for degradation
Drug substance propertiesLow bulk density, crystalline, single stable polymorphPrimary amine salt
![Page 12: PAT and Quality by Design exemplified in a Mock P2 ...gmpeye.co.kr/gmpguidesandguidelines/quality by design... · 3 Introduction EFPIA PAT Topic Group Chris Potter AstraZeneca: Chairman](https://reader030.fdocuments.us/reader030/viewer/2022013107/5b5877407f8b9a655d8c0ad1/html5/thumbnails/12.jpg)
12
Identified that fluidised-bed drying is the critical step and the level of hydrolysis product (des-ethyl examplain) is a critical attribute
Based on development work and mechanistic process understanding Design Space for granulation and fluid bed drying have been developed
Packaging in Aclar with aluminum layer is sufficient from drug product stability studies
Removal of end product testing has been derived based on the developed Control Strategy
“Examplain” Tablets Brief Description
![Page 13: PAT and Quality by Design exemplified in a Mock P2 ...gmpeye.co.kr/gmpguidesandguidelines/quality by design... · 3 Introduction EFPIA PAT Topic Group Chris Potter AstraZeneca: Chairman](https://reader030.fdocuments.us/reader030/viewer/2022013107/5b5877407f8b9a655d8c0ad1/html5/thumbnails/13.jpg)
13
“Examplain” Tablets Scientific Principles
PrinciplesA Control Strategy has been derived after completion of process understanding studies and application of Risk Management toolsSpecifications can be set scientifically based on relationship to safety and efficacyCritical to quality steps and attributes are identifiedRegulatory flexibility can be proposedReal time release can be justified
![Page 14: PAT and Quality by Design exemplified in a Mock P2 ...gmpeye.co.kr/gmpguidesandguidelines/quality by design... · 3 Introduction EFPIA PAT Topic Group Chris Potter AstraZeneca: Chairman](https://reader030.fdocuments.us/reader030/viewer/2022013107/5b5877407f8b9a655d8c0ad1/html5/thumbnails/14.jpg)
14
Scientific PrinciplesIterative Approach
Target Product Profile
Drug substance properties; prior knowledge
Proposed formulation and manufacturing process
Determination of Cause – Effect relationships
(Risk Identification with subsequent Risk Analysis)
Risk-based classification (Risk Evaluation)
Parameters to investigate (e.g. by DOE)(Risk Reduction 1: proposal 2: verified)
FORMULATION FORMULATION DESIGN SPACEDESIGN SPACE
PROCESS PROCESS DESIGN SPACE DESIGN SPACE
BY UNIT OPERATIONBY UNIT OPERATIONCONTROL CONTROL STRATEGYSTRATEGY
Form
ulat
ion
unde
rsta
ndin
gFo
rmul
atio
n un
ders
tand
ing
Proc
ess
unde
rsta
ndin
gPr
oces
s un
ders
tand
ing
ReRe --
eval
uatio
n an
d co
nfirm
atio
nev
alua
tion
and
conf
irmat
ion
ReRe --
eval
uatio
n an
d co
nfirm
atio
nev
alua
tion
and
conf
irmat
ion
Derived
![Page 15: PAT and Quality by Design exemplified in a Mock P2 ...gmpeye.co.kr/gmpguidesandguidelines/quality by design... · 3 Introduction EFPIA PAT Topic Group Chris Potter AstraZeneca: Chairman](https://reader030.fdocuments.us/reader030/viewer/2022013107/5b5877407f8b9a655d8c0ad1/html5/thumbnails/15.jpg)
15
Scientific PrinciplesRisk Management
PrinciplesRisk Management according ICH Q9 approach has been appliedPrior knowledge, experience from other projects and the application of DoE are the main driver for getting fact-based mechanistic process understanding An initial risk assessment identifying potential interactions between unit of operations and key attributes is the starting point for the development workRisk assessment, control and communication had been constantly updated (reviewed) within the development workTools like e.g. Ishikawa diagram and FMEA have been used for the identification and quantification of risks
![Page 16: PAT and Quality by Design exemplified in a Mock P2 ...gmpeye.co.kr/gmpguidesandguidelines/quality by design... · 3 Introduction EFPIA PAT Topic Group Chris Potter AstraZeneca: Chairman](https://reader030.fdocuments.us/reader030/viewer/2022013107/5b5877407f8b9a655d8c0ad1/html5/thumbnails/16.jpg)
16
Risk Management approach Simplified view (frequent review)
Qua
lity
Attr
ibut
es
Unit operation
Granulation Drying Blending CompressionDispensation
Dissolution
Disintegration
Hardness
Assay
ContentUniformity
Degradation
Stability
Appearance Prior KnowlledgePrior Knowlledge
Identification
Water
Microbiology DoE Prior Knowlledge
low Prior knowledge
Original high Controlled by a) process understanding or b) included in the control strategy
Process understanding Original high influence: Development studies have shown to be not critical to quality
Control Strategy Original high influence: Development studies have shown to have potential influence to quality. Therefore control measurements have been introduced.
First review cycle
Second review cycle
Third review cycle
![Page 17: PAT and Quality by Design exemplified in a Mock P2 ...gmpeye.co.kr/gmpguidesandguidelines/quality by design... · 3 Introduction EFPIA PAT Topic Group Chris Potter AstraZeneca: Chairman](https://reader030.fdocuments.us/reader030/viewer/2022013107/5b5877407f8b9a655d8c0ad1/html5/thumbnails/17.jpg)
17
Part 2 – Mock P.2 SubmissionTPP linked to safety and efficacy Initial Risk AssessmentFormulation DevelopmentProcess Development
GranulationFluid bed drying
Control StrategyImpact on End Product TestingRegulatory FlexibilityDiscussion
![Page 18: PAT and Quality by Design exemplified in a Mock P2 ...gmpeye.co.kr/gmpguidesandguidelines/quality by design... · 3 Introduction EFPIA PAT Topic Group Chris Potter AstraZeneca: Chairman](https://reader030.fdocuments.us/reader030/viewer/2022013107/5b5877407f8b9a655d8c0ad1/html5/thumbnails/18.jpg)
18
TPP Examplain linked to safety and efficacy in patients
TPP summarises the quality attributes of the product required to meet the needs of the patient for safety and efficacy Safety is primarily assured by des-ethyl examplain being less than 2% at the end of shelf life
Limit has been qualified in toxicological studiesPharmacopoeial ranges for acceptable uniformity of content are much less than that seen for variability of plasma levels in Phase 2 and Phase 3 clinical studiesAppropriate GMP standards during manufacture assure microbiological quality of this orally administered drug
Efficacy is assured for this BCS Class I drug substance by application of a dissolution test during development*Efficacy is assured by application of a lower limit for uniformity of dosage units (similar to the safety justification)
*FDA Guidance for Industry-‘Biowaver Guidance’, CDER 2000 has been applied
![Page 19: PAT and Quality by Design exemplified in a Mock P2 ...gmpeye.co.kr/gmpguidesandguidelines/quality by design... · 3 Introduction EFPIA PAT Topic Group Chris Potter AstraZeneca: Chairman](https://reader030.fdocuments.us/reader030/viewer/2022013107/5b5877407f8b9a655d8c0ad1/html5/thumbnails/19.jpg)
19
Introduction Manufacturing Process (simplified scheme)
Unit Operations
Dispensation
Blending
Fluidized Bed Dryer
Packaging
Tableting
Granulation
Air
Scale
Raw Materials
![Page 20: PAT and Quality by Design exemplified in a Mock P2 ...gmpeye.co.kr/gmpguidesandguidelines/quality by design... · 3 Introduction EFPIA PAT Topic Group Chris Potter AstraZeneca: Chairman](https://reader030.fdocuments.us/reader030/viewer/2022013107/5b5877407f8b9a655d8c0ad1/html5/thumbnails/20.jpg)
20
Initial Risk-Based Classification:Impact of Unit Operations on Quality
Unit operations / Quality attributes
Dispensing (Raw Material
Properties) Granulation Drying
Blending (Magnesium
Stearate) Tableting Packaging
Dissolution Prior knowledge Prior knowledge
Disintegration Prior knowledge Prior knowledge
Hardness Prior knowledge Prior knowledge Prior knowledge Prior knowledge
Assay Prior knowledge Prior knowledge Prior knowledge Prior knowledge Prior knowledge
Content uniformity Prior knowledge Prior knowledge
Degradation Prior knowledge Prior knowledge Prior knowledge
Stability Prior knowledge Prior knowledge Prior knowledge Prior knowledge Prior knowledge
Appearance Prior knowledge Prior knowledge Prior knowledge Prior knowledge
Identification Prior knowledge Prior knowledge Prior knowledge Prior knowledge Prior knowledge
Water Prior knowledge Prior knowledge Prior knowledge Prior knowledge
Microbiology Prior knowledge Prior knowledge Prior knowledge Prior knowledge
![Page 21: PAT and Quality by Design exemplified in a Mock P2 ...gmpeye.co.kr/gmpguidesandguidelines/quality by design... · 3 Introduction EFPIA PAT Topic Group Chris Potter AstraZeneca: Chairman](https://reader030.fdocuments.us/reader030/viewer/2022013107/5b5877407f8b9a655d8c0ad1/html5/thumbnails/21.jpg)
21
Conclusion from initial risk evaluationDOE Plan Formulation Development
Factors to study:Drug substance particle sizeSelection of other raw materials (lactose vs. mannitol) and ranges (e.g. magnesium stearate)Hardness of tabletsTablet dissolution Evaluation of water content in tabletsInitial evaluation of content uniformity
![Page 22: PAT and Quality by Design exemplified in a Mock P2 ...gmpeye.co.kr/gmpguidesandguidelines/quality by design... · 3 Introduction EFPIA PAT Topic Group Chris Potter AstraZeneca: Chairman](https://reader030.fdocuments.us/reader030/viewer/2022013107/5b5877407f8b9a655d8c0ad1/html5/thumbnails/22.jpg)
22
Pharmaceutical Development –Transformation into Practice
Target Product Profile
Drug Substance Properties
Proposed Formulation andManufacturing Process
Determination of Cause –Effect Relationships
Risk-based Classification
Derived Action Plan andParameters to investigate
Reevaluation and Confirmationof Critical Process Parameters
Product Performance
Prior Knowledge
Prior knowledge
Risk IdentificationRisk Analysis
Quantified Risk(Evaluation)
e.g. DOE (1st DerivativeDesign Space)
Risk Reduction
![Page 23: PAT and Quality by Design exemplified in a Mock P2 ...gmpeye.co.kr/gmpguidesandguidelines/quality by design... · 3 Introduction EFPIA PAT Topic Group Chris Potter AstraZeneca: Chairman](https://reader030.fdocuments.us/reader030/viewer/2022013107/5b5877407f8b9a655d8c0ad1/html5/thumbnails/23.jpg)
23
Formulation DevelopmentDrug Substance Particle Size
Due to the basic nature of examplain (pKa = 10.1 in aqueous solution at 25ºC), the solubility is greatest at low pH values and begins to drop as the pH rises.Tablets manufactured from drug substance with small (d90 < 15 µm, d10 < 5 µm) and large (d90< 180 µm, d10 < 30 µm) particles showed essentially equivalent dissolution performance (Chapter: 3.2.P.2.1.1;Figure 3).
![Page 24: PAT and Quality by Design exemplified in a Mock P2 ...gmpeye.co.kr/gmpguidesandguidelines/quality by design... · 3 Introduction EFPIA PAT Topic Group Chris Potter AstraZeneca: Chairman](https://reader030.fdocuments.us/reader030/viewer/2022013107/5b5877407f8b9a655d8c0ad1/html5/thumbnails/24.jpg)
24
Formulation DevelopmentRaw Material Selection
Examplain hydrochloride was shown to be incompatible with lactose, as expected due to the ability of the primary amine in the drug substance to undergo a Maillard reaction.No evidence was seen for degradation of drug substance in the presence of microcrystalline cellulose, mannitol, dibasic calcium phosphate, povidone K-30, hydroxypropylmethyl cellulose, croscarmellose sodium or magnesium stearate.The binder concentration in range of 4% and 6% has no significant effect on tablet dissolution or disintegration.
![Page 25: PAT and Quality by Design exemplified in a Mock P2 ...gmpeye.co.kr/gmpguidesandguidelines/quality by design... · 3 Introduction EFPIA PAT Topic Group Chris Potter AstraZeneca: Chairman](https://reader030.fdocuments.us/reader030/viewer/2022013107/5b5877407f8b9a655d8c0ad1/html5/thumbnails/25.jpg)
25
Formulation DevelopmentHardness of Tablets
Hardness above or equal 4 kP produces acceptable tablets
Compression Force (kN) vs Crushing Strength (kP)Effect of Tablet Production Rate
0.00
2.00
4.00
6.00
8.00
10.00
12.00
14.00
16.00
0 5 10 15 20 25 30 35
Compression Force (kN)
Cru
shin
g St
reng
th (k
P)
20mg Examplain Hydrochloride @100K TPH
20mg Examplain Hydrochloride @200K TPH
![Page 26: PAT and Quality by Design exemplified in a Mock P2 ...gmpeye.co.kr/gmpguidesandguidelines/quality by design... · 3 Introduction EFPIA PAT Topic Group Chris Potter AstraZeneca: Chairman](https://reader030.fdocuments.us/reader030/viewer/2022013107/5b5877407f8b9a655d8c0ad1/html5/thumbnails/26.jpg)
26
Formulation DevelopmentWater Content
Studies show that a maximum water content of 2%w/w in tablets produces acceptably stable drug product
0
0.5
1
1.5
2
2.5
3
3.5
Initial 6w 12w 6mo
% d
es-e
thyl
exa
mpl
ain
1.8%2.4%2.8%3.5%
One stability batch containing
2.4% water content showed
sufficient stability
![Page 27: PAT and Quality by Design exemplified in a Mock P2 ...gmpeye.co.kr/gmpguidesandguidelines/quality by design... · 3 Introduction EFPIA PAT Topic Group Chris Potter AstraZeneca: Chairman](https://reader030.fdocuments.us/reader030/viewer/2022013107/5b5877407f8b9a655d8c0ad1/html5/thumbnails/27.jpg)
27
Formulation DevelopmentWater Content /Packaging material
Aclar as foil for unit dose blisters (aluminium foil backing) showed improved stability compared with unpacked tablets after storage at 40°C/75% RH for 6 months
The batch of tablets contained 2.4% moisture content.
0
0.5
1
1.5
2
% d
eset
hyl e
xam
plai
n
0 2 4 6
Time (months)
Effect of packaging on des-ethyl examplain levels in drug product at 40C/75%RH
40/75 Open40/75 Aclar
![Page 28: PAT and Quality by Design exemplified in a Mock P2 ...gmpeye.co.kr/gmpguidesandguidelines/quality by design... · 3 Introduction EFPIA PAT Topic Group Chris Potter AstraZeneca: Chairman](https://reader030.fdocuments.us/reader030/viewer/2022013107/5b5877407f8b9a655d8c0ad1/html5/thumbnails/28.jpg)
28
Formulation DevelopmentMagnesium Stearate Concentration
In the range of 1% to 3% no significant effects on compression or dissolution at this level have been demonstrated
0
20
40
60
80
100
120
0 5 10 15 20 25 30 45
Time (minutes)
Mea
n %
dis
solu
tion
1% Mg St
2% Mg St
3% Mg St
Compression Force (kN) vs Crushing Strength (kP)Effect of Lubricant Level
0.00
2.00
4.00
6.00
8.00
10.00
12.00
14.00
16.00
0 5 10 15 20 25 30 35
Compression Force (kN)
Cru
shin
g St
reng
th (K
p)
20mg Examplain Hydrochloride @1% MgSt20mg Examplain Hydrochloride @2% MgSt20mg Examplain Hydrochloride @3% MgSt
![Page 29: PAT and Quality by Design exemplified in a Mock P2 ...gmpeye.co.kr/gmpguidesandguidelines/quality by design... · 3 Introduction EFPIA PAT Topic Group Chris Potter AstraZeneca: Chairman](https://reader030.fdocuments.us/reader030/viewer/2022013107/5b5877407f8b9a655d8c0ad1/html5/thumbnails/29.jpg)
29
First Review of Risk AssessmentUnit operations / Quality attributes
Dispensing (Raw Material
Properties) Granulation Drying
Blending (Magnesium
Stearate) Tableting Packaging
Dissolution Fig 3 (Particle size API)
Prior knowledge Fig 9 Fig 9 Prior knowledge
Disintegration
Fig 3 (deduced) Prior knowledge Fig 9 & 3.2.P.2.1.1 & 3.2.P.2.2.3 (deduced)
Fig 9 & 3.2.P.2.1.1 & 3.2.P.2.2.3 (deduced)
Prior knowledge
Hardness Prior knowledge Prior knowledge Prior knowledge Fig 8 Fig 7 Prior knowledge
Assay Prior knowledge Prior knowledge Prior knowledge Prior knowledge Prior knowledge
Content uniformity Prior knowledge Prior knowledge
Degradation Prior knowledge Prior knowledge Prior knowledge
Stability
Prior knowledge Prior knowledge Water content less than 2% based on Formulation Development
Prior knowledge Prior knowledge Prior knowledge
Appearance Prior knowledge Prior knowledge Prior knowledge Prior knowledge
Identification Based on Control Strategy
Prior knowledge Prior knowledge Prior knowledge Prior knowledge Prior knowledge
Water Prior knowledge Prior knowledge To be controlled Prior knowledge Prior knowledge
Microbiology Specification of starting material
Prior knowledge Prior knowledge Prior knowledge Prior knowledge
![Page 30: PAT and Quality by Design exemplified in a Mock P2 ...gmpeye.co.kr/gmpguidesandguidelines/quality by design... · 3 Introduction EFPIA PAT Topic Group Chris Potter AstraZeneca: Chairman](https://reader030.fdocuments.us/reader030/viewer/2022013107/5b5877407f8b9a655d8c0ad1/html5/thumbnails/30.jpg)
30
Formulation Development Conclusions
A dissolution test has been developed, which is an excellent surrogate for in vivo absorptionDesign Space boundaries for Mg stearateconcentration are 1% and 3%Development studies showed relationship between water content, degradation, and stability as critical
further study during process development and consideration in the control strategy
Manufacturing process development has to cover further potential interactions not evaluated by formulation development (next slide)
![Page 31: PAT and Quality by Design exemplified in a Mock P2 ...gmpeye.co.kr/gmpguidesandguidelines/quality by design... · 3 Introduction EFPIA PAT Topic Group Chris Potter AstraZeneca: Chairman](https://reader030.fdocuments.us/reader030/viewer/2022013107/5b5877407f8b9a655d8c0ad1/html5/thumbnails/31.jpg)
31
Process DevelopmentNext Steps
Process Development focussed on evaluation of unit operations and their impact on quality attributes
Granulation – content uniformity, dissolution / disintegrationDrying – water content, content uniformityBlending – content uniformityTableting – assay, content uniformityPackaging – water content
![Page 32: PAT and Quality by Design exemplified in a Mock P2 ...gmpeye.co.kr/gmpguidesandguidelines/quality by design... · 3 Introduction EFPIA PAT Topic Group Chris Potter AstraZeneca: Chairman](https://reader030.fdocuments.us/reader030/viewer/2022013107/5b5877407f8b9a655d8c0ad1/html5/thumbnails/32.jpg)
32
Process DevelopmentGranulation
All parameters relevant to wet granulation were identified from the Ishikawa diagram and introduced into a detailed risk assessment (FMEA)
To establish those process parameters associated with the critical to quality attribute, water content
Process understanding generated through prior knowledge, experimental development data (DoE studies at 1Kg and 25 Kg scale) and use of multivariate experimental plans with in-line analytical applications
![Page 33: PAT and Quality by Design exemplified in a Mock P2 ...gmpeye.co.kr/gmpguidesandguidelines/quality by design... · 3 Introduction EFPIA PAT Topic Group Chris Potter AstraZeneca: Chairman](https://reader030.fdocuments.us/reader030/viewer/2022013107/5b5877407f8b9a655d8c0ad1/html5/thumbnails/33.jpg)
33
Process DevelopmentKey Process Variables for Wet Granulation
Based on general process experience and prior knowledge the following key process variables will be considered in DOE studies for examplain
Wet granulation parameters Input material attributes Mixing speed API particle size Water addition rate Mannitol particle size Mixing time
![Page 34: PAT and Quality by Design exemplified in a Mock P2 ...gmpeye.co.kr/gmpguidesandguidelines/quality by design... · 3 Introduction EFPIA PAT Topic Group Chris Potter AstraZeneca: Chairman](https://reader030.fdocuments.us/reader030/viewer/2022013107/5b5877407f8b9a655d8c0ad1/html5/thumbnails/34.jpg)
34
Process DevelopmentInfluence of Mixing Speed & Water Addition Rate on Disintegration
D isinteg ration
M ixing sp eed
Wat
er a
dditi
on ra
te
D is integ ration
F a ster
yellow = meets pharmacopoeialquality requirements for an immediate
release dosage form
These DOE studies showed that factors like mixing speed and water addition rate are the most important on disintegration
![Page 35: PAT and Quality by Design exemplified in a Mock P2 ...gmpeye.co.kr/gmpguidesandguidelines/quality by design... · 3 Introduction EFPIA PAT Topic Group Chris Potter AstraZeneca: Chairman](https://reader030.fdocuments.us/reader030/viewer/2022013107/5b5877407f8b9a655d8c0ad1/html5/thumbnails/35.jpg)
35
Process DevelopmentDOE Coefficients for Disintegration
Relative Importance of Process Parameters on Disintegration could be derived from evaluation of Coefficient Plot from Partial Least Squares (PLS) Model (Data out of DoE studies)
-3
-2
-1
0
1
2
3
4
Drug Substance Mannitol PS Mixing Speed Water Amount Wet Mixing Time Compression Force
Series1
DoE Coefficients for Disintegration
Key process variables could be confirmed with nosignificant influence on disintegration
![Page 36: PAT and Quality by Design exemplified in a Mock P2 ...gmpeye.co.kr/gmpguidesandguidelines/quality by design... · 3 Introduction EFPIA PAT Topic Group Chris Potter AstraZeneca: Chairman](https://reader030.fdocuments.us/reader030/viewer/2022013107/5b5877407f8b9a655d8c0ad1/html5/thumbnails/36.jpg)
36
Process DevelopmentSummary
Water addition rate and time can be continuously adjusted within the design space to obtain highly consistent granule properties mainly with respect to flowability, compressibility, degradation, and suitability as input to the next processing step
This acceptable region could be considered as the Design Space for water addition rate and time (see graphical presentation)
![Page 37: PAT and Quality by Design exemplified in a Mock P2 ...gmpeye.co.kr/gmpguidesandguidelines/quality by design... · 3 Introduction EFPIA PAT Topic Group Chris Potter AstraZeneca: Chairman](https://reader030.fdocuments.us/reader030/viewer/2022013107/5b5877407f8b9a655d8c0ad1/html5/thumbnails/37.jpg)
37
log
(wat
er a
dditi
on ti
me)
Disintegration acceptable
Log (Water addition rate)
Fines
Bad Degradation
High level of fines
in dried granule
Increased risk of
degradation in tablets
Good = ‘acceptable water
content for fluid bed drying’
Process DevelopmentSummary
Design Space for water addition rate
![Page 38: PAT and Quality by Design exemplified in a Mock P2 ...gmpeye.co.kr/gmpguidesandguidelines/quality by design... · 3 Introduction EFPIA PAT Topic Group Chris Potter AstraZeneca: Chairman](https://reader030.fdocuments.us/reader030/viewer/2022013107/5b5877407f8b9a655d8c0ad1/html5/thumbnails/38.jpg)
38
Design Space for Wet - GranulationSummary
Multivariate for tablet disintegration, content uniformity and degradation parameters
Water addition rateMixer speedTime
Output optimised for water content for drying Could use multivariate model to predict disintegrationChange of scale can be understoodArea of failure not always found (disintegration)
![Page 39: PAT and Quality by Design exemplified in a Mock P2 ...gmpeye.co.kr/gmpguidesandguidelines/quality by design... · 3 Introduction EFPIA PAT Topic Group Chris Potter AstraZeneca: Chairman](https://reader030.fdocuments.us/reader030/viewer/2022013107/5b5877407f8b9a655d8c0ad1/html5/thumbnails/39.jpg)
39
Second Review of Risk Assessment
Unit operations/ Quality attributes
Dispensing (Raw Material
Properties)Granulation Drying
Blending (Magnesium
Stearate)Tableting Packaging
DissolutionFig 3 (Particle size API)
see 3.2.P.2.3.1. Prior knowledge Fig 9 Fig 9 Prior knowledge
Disintegration
Fig 3 (deduced) see 3.2.P.2.3.1. Prior knowledge Fig 9 & 3.2.P.2.1.1 & 3.2.P.2.2.3 (deduced)
Fig 9 & 3.2.P.2.1.1 & 3.2.P.2.2.3 (deduced)
Prior knowledge
Hardness Prior knowledge Prior knowledge Prior knowledge Fig 8 Fig 7 Prior knowledge
Assay Prior knowledge Prior knowledge Prior knowledge Prior knowledge Prior knowledge
Content uniformity Prior knowledge ???? Prior knowledge
Degradation Prior knowledge see 3.2.P.2.3.1. Prior knowledge Prior knowledge
Stability
Prior knowledge Prior knowledge Water content less than 2% based on Formulation Development
Prior knowledge Prior knowledge Prior knowledge
Appearance Prior knowledge Prior knowledge Prior knowledge Prior knowledge
IdentificationBased on Control Strategy
Prior knowledge Prior knowledge Prior knowledge Prior knowledge Prior knowledge
Water Prior knowledge Prior knowledge To be controlled Prior knowledge Prior knowledge
MicrobiologySpecification of starting material
Prior knowledge Prior knowledge Prior knowledge Prior knowledge
![Page 40: PAT and Quality by Design exemplified in a Mock P2 ...gmpeye.co.kr/gmpguidesandguidelines/quality by design... · 3 Introduction EFPIA PAT Topic Group Chris Potter AstraZeneca: Chairman](https://reader030.fdocuments.us/reader030/viewer/2022013107/5b5877407f8b9a655d8c0ad1/html5/thumbnails/40.jpg)
40
Control StrategyMonitoring of Granulation
Monitoring the high shear mixing process by power consumption or other techniques such as acoustic spectroscopy offers PAT opportunities for better process understanding and advanced control, e.g. of end-point.
Power
Dry mix Wet granuleWet Granulation
Red – input variables Green – derived parameters
wet mass
TabletDisintegration
Blue – in-line measurements
Mixing speedMixing timeWater amount
API Size distribution Power
Dry mix Wet granuleWet Granulation
Red – input variables Green – derived parameters
wet mass
TabletDisintegration
Blue – in-line measurements
Mixing speedMixing timeWater addition rate
![Page 41: PAT and Quality by Design exemplified in a Mock P2 ...gmpeye.co.kr/gmpguidesandguidelines/quality by design... · 3 Introduction EFPIA PAT Topic Group Chris Potter AstraZeneca: Chairman](https://reader030.fdocuments.us/reader030/viewer/2022013107/5b5877407f8b9a655d8c0ad1/html5/thumbnails/41.jpg)
41
Control StrategyProcess Trajectories for Wet GranulationProcess trajectories based on power consumption monitoring are established on 1 kg scale and confirmed on 25 kg scale.
Pow
er c
onsu
mpt
ion
(kW
)
Wet mixing time (min)
Disintegration OK but difficult to obtain sufficient hardness, and some potential for degradation
Disintegration OK but flowability of dry granule low
End-point: 6 Min. after peak
Design Space - Product quality assured
![Page 42: PAT and Quality by Design exemplified in a Mock P2 ...gmpeye.co.kr/gmpguidesandguidelines/quality by design... · 3 Introduction EFPIA PAT Topic Group Chris Potter AstraZeneca: Chairman](https://reader030.fdocuments.us/reader030/viewer/2022013107/5b5877407f8b9a655d8c0ad1/html5/thumbnails/42.jpg)
42
Control StrategyGranulation
The granulation process is controlled by measuring the power consumption during granulationThe water amount per mass of granulate and the addition feed rate are fixed based on our process understanding (DOE)Power consumption peak as starting point for 6 min. interval to finish wet massing (compensates raw material properties (e.g. water content, particle size distributions)The wet granulation Design Space is part of the control strategy to provide additional assurance of satisfactory granulation
![Page 43: PAT and Quality by Design exemplified in a Mock P2 ...gmpeye.co.kr/gmpguidesandguidelines/quality by design... · 3 Introduction EFPIA PAT Topic Group Chris Potter AstraZeneca: Chairman](https://reader030.fdocuments.us/reader030/viewer/2022013107/5b5877407f8b9a655d8c0ad1/html5/thumbnails/43.jpg)
43
Process DevelopmentFluid-bed Drying
Detailed risk assessment (FMEA) identified fluid bed drying as a possible critical process step with respect to:
Water contentDes-ethyl examplain impurity level of NMT 2% at the end of shelf lifeEnsuring disintegration and dissolution characteristicsContent uniformity
![Page 44: PAT and Quality by Design exemplified in a Mock P2 ...gmpeye.co.kr/gmpguidesandguidelines/quality by design... · 3 Introduction EFPIA PAT Topic Group Chris Potter AstraZeneca: Chairman](https://reader030.fdocuments.us/reader030/viewer/2022013107/5b5877407f8b9a655d8c0ad1/html5/thumbnails/44.jpg)
44
Process DevelopmentFluid-bed Drying
Based on prior knowledge the impact of high level of fines could result in:
poor flow during tablettingincreased variability in unit dose masscontent uniformityeffect on disintegration or dissolution
Water content of up to 2% w/w in tablets produces acceptable drug product stability
Water content does not change after granulation upon tabletting and packing
Over-drying generated increased levels of fine particles
Should be investigated within the development work
![Page 45: PAT and Quality by Design exemplified in a Mock P2 ...gmpeye.co.kr/gmpguidesandguidelines/quality by design... · 3 Introduction EFPIA PAT Topic Group Chris Potter AstraZeneca: Chairman](https://reader030.fdocuments.us/reader030/viewer/2022013107/5b5877407f8b9a655d8c0ad1/html5/thumbnails/45.jpg)
45
Process DevelopmentKey Process Variables for FBD
Process variables
Drying parameters Input material attributes Inlet air temperature Water content Inlet air humidity Granule particle size distribution Air flow rate Fill level Filter sock cycle Heating rate Cooling rate Quality attributes
Dried granule Tablet Particle size distribution (fines) Disintegration Water content Dissolution Degradation (des-ethyl examplain) Weight uniformity Content uniformity
![Page 46: PAT and Quality by Design exemplified in a Mock P2 ...gmpeye.co.kr/gmpguidesandguidelines/quality by design... · 3 Introduction EFPIA PAT Topic Group Chris Potter AstraZeneca: Chairman](https://reader030.fdocuments.us/reader030/viewer/2022013107/5b5877407f8b9a655d8c0ad1/html5/thumbnails/46.jpg)
46
Process DevelopmentDOE Plan
Established relationships between process variables and quality attributes of the dried granule
including equipment settings and attributes from the input wet granules1 kg scaleMonitoring conventional equipment parameters (inlet, bed and outlet temperatures, air flow etc)Additional on-line NIR spectroscopy and Lasentec FBRM methods to measure water content and particle size distribution
![Page 47: PAT and Quality by Design exemplified in a Mock P2 ...gmpeye.co.kr/gmpguidesandguidelines/quality by design... · 3 Introduction EFPIA PAT Topic Group Chris Potter AstraZeneca: Chairman](https://reader030.fdocuments.us/reader030/viewer/2022013107/5b5877407f8b9a655d8c0ad1/html5/thumbnails/47.jpg)
47
Process DevelopmentDegradation and generation of fines
Air flow
Inle
t tem
pera
ture
Fines
Air flow
Inle
t tem
pera
ture
Degradation
Air flow
Inle
t tem
pera
ture
Fines
Air flow
Inle
t tem
pera
ture
Fines
Air flow
Inle
t tem
pera
ture
Degradation
Air flow
Inle
t tem
pera
ture
Degradation
Red = does not meet quality requirements1 kg scale
![Page 48: PAT and Quality by Design exemplified in a Mock P2 ...gmpeye.co.kr/gmpguidesandguidelines/quality by design... · 3 Introduction EFPIA PAT Topic Group Chris Potter AstraZeneca: Chairman](https://reader030.fdocuments.us/reader030/viewer/2022013107/5b5877407f8b9a655d8c0ad1/html5/thumbnails/48.jpg)
48
Air flow
Inle
t tem
pera
ture
Degradation and fines
Air flow
Inle
t tem
pera
ture
Degradation and fines
Air flow
Inle
t tem
pera
ture
Degradation and fines
Process DevelopmentCombination of Failure Modes
![Page 49: PAT and Quality by Design exemplified in a Mock P2 ...gmpeye.co.kr/gmpguidesandguidelines/quality by design... · 3 Introduction EFPIA PAT Topic Group Chris Potter AstraZeneca: Chairman](https://reader030.fdocuments.us/reader030/viewer/2022013107/5b5877407f8b9a655d8c0ad1/html5/thumbnails/49.jpg)
49Air flow
Inle
t tem
pera
ture
Weight uniformity (RSD)
>3%
<1.5%
Air flow
Inle
t tem
pera
ture
Weight uniformity (RSD)
>3%
<1.5%
Process DevelopmentTablet Weight Uniformity
![Page 50: PAT and Quality by Design exemplified in a Mock P2 ...gmpeye.co.kr/gmpguidesandguidelines/quality by design... · 3 Introduction EFPIA PAT Topic Group Chris Potter AstraZeneca: Chairman](https://reader030.fdocuments.us/reader030/viewer/2022013107/5b5877407f8b9a655d8c0ad1/html5/thumbnails/50.jpg)
50
Process DevelopmentDrying Curves
Drying experiments at 1 kg scaleUsing wet granulate with water content of 18±0.5% (as is routinely produced by the granulation process)Inlet temperature and air flow were variedStopped when the water content was in the range 1.5-2.0%Water content of the granules, and their particle size distribution were monitored on-line
Confirmed at larger scaleExperiments do not take account of time
![Page 51: PAT and Quality by Design exemplified in a Mock P2 ...gmpeye.co.kr/gmpguidesandguidelines/quality by design... · 3 Introduction EFPIA PAT Topic Group Chris Potter AstraZeneca: Chairman](https://reader030.fdocuments.us/reader030/viewer/2022013107/5b5877407f8b9a655d8c0ad1/html5/thumbnails/51.jpg)
51
Process DevelopmentDrying Process Trajectories (1 kg Scale)
% H2O
2.0%1.5%
18.5%
Drying time
17.5% 12
34
5
6789
% H2O
2.0%1.5%
18.5%
Drying time
17.5% 12
34
5
6789
![Page 52: PAT and Quality by Design exemplified in a Mock P2 ...gmpeye.co.kr/gmpguidesandguidelines/quality by design... · 3 Introduction EFPIA PAT Topic Group Chris Potter AstraZeneca: Chairman](https://reader030.fdocuments.us/reader030/viewer/2022013107/5b5877407f8b9a655d8c0ad1/html5/thumbnails/52.jpg)
52
Process DevelopmentDrying Process Trajectories – Summary
Experiment / Process Trajectory
% des-ethyl examplain (<1.0%)
% fines (< x µm) (<15%)
Weight uniformity
(RSD)
Acceptable quality?
1 1.7 4 1.3% No – high des-ethyl level
2 1.3 7 1.7% No – high des-ethyl level
3 0.3 5 1.5% Yes 4 0.3 5 1.4% Yes 5 0.2 6 1.7% Yes 6 0.3 4 1.3% Yes 7 0.2 7 1.6% Yes 8 0.2 17 3.4% No – poor flow impacts
weight uniformity 9 0.2 20 5.3% No – poor flow impacts
weight uniformity
![Page 53: PAT and Quality by Design exemplified in a Mock P2 ...gmpeye.co.kr/gmpguidesandguidelines/quality by design... · 3 Introduction EFPIA PAT Topic Group Chris Potter AstraZeneca: Chairman](https://reader030.fdocuments.us/reader030/viewer/2022013107/5b5877407f8b9a655d8c0ad1/html5/thumbnails/53.jpg)
53
Process DevelopmentDrying Process Trajectories (25 kg Scale)
% H2O
2.0%1.5%
18.5%
Drying time
17.5%
Trajectories describing the boundaries of the design space where product quality is assured
Test batches (see text)
ICH registration stability batches
% H2O
2.0%1.5%
18.5%
Drying time
17.5%
Trajectories describing the boundaries of the design space where product quality is assured
Test batches (see text)
ICH registration stability batches
![Page 54: PAT and Quality by Design exemplified in a Mock P2 ...gmpeye.co.kr/gmpguidesandguidelines/quality by design... · 3 Introduction EFPIA PAT Topic Group Chris Potter AstraZeneca: Chairman](https://reader030.fdocuments.us/reader030/viewer/2022013107/5b5877407f8b9a655d8c0ad1/html5/thumbnails/54.jpg)
54
Fluid-bed DryingDOE Results
Confirmed the existence of two failure modes
degradation / hydrolysis of the API (linked to granule water content)generation of fines (by breaking down the granules)
Impact of inlet temperatures and flow rates on the amount of degradation and level of fines
different combinations of these parameters are required to avoid each failure modecontrol of granule water content alone is not sufficient
![Page 55: PAT and Quality by Design exemplified in a Mock P2 ...gmpeye.co.kr/gmpguidesandguidelines/quality by design... · 3 Introduction EFPIA PAT Topic Group Chris Potter AstraZeneca: Chairman](https://reader030.fdocuments.us/reader030/viewer/2022013107/5b5877407f8b9a655d8c0ad1/html5/thumbnails/55.jpg)
55
Fluid-bed DryingDOE Results
Strong interaction between the effects of inlet air temperature and flow rate on granule properties is consistent with previous experienceGranule quality is sensitive to
inlet air temperature and flow ratewater contentparticle size distribution of the in-going wet granulate
Inlet air humidity is not critical
![Page 56: PAT and Quality by Design exemplified in a Mock P2 ...gmpeye.co.kr/gmpguidesandguidelines/quality by design... · 3 Introduction EFPIA PAT Topic Group Chris Potter AstraZeneca: Chairman](https://reader030.fdocuments.us/reader030/viewer/2022013107/5b5877407f8b9a655d8c0ad1/html5/thumbnails/56.jpg)
56
Design Space for Fluid Bed DryingSummary
Multivariate for degradation, disintegration, uniformity of content
Inlet temperatureAir flowDrying time
Trajectory for water content, a critical parameterChange of scale understoodAreas of failure found in this caseClear control strategy
![Page 57: PAT and Quality by Design exemplified in a Mock P2 ...gmpeye.co.kr/gmpguidesandguidelines/quality by design... · 3 Introduction EFPIA PAT Topic Group Chris Potter AstraZeneca: Chairman](https://reader030.fdocuments.us/reader030/viewer/2022013107/5b5877407f8b9a655d8c0ad1/html5/thumbnails/57.jpg)
57
Design Space for DryingGraphical Description
Known edge of failure due to fines
% H2O
2.0%1.5%
18.5%
Drying time
Known edge of failure due to degradation
Regions of uncertainty17.5%
Trajectories describing the boundaries of the design space where product quality is assured
Known edge of failure due to fines
% H2O
2.0%1.5%
18.5%
Drying time
Known edge of failure due to degradation
Regions of uncertainty17.5%
Trajectories describing the boundaries of the design space where product quality is assured
![Page 58: PAT and Quality by Design exemplified in a Mock P2 ...gmpeye.co.kr/gmpguidesandguidelines/quality by design... · 3 Introduction EFPIA PAT Topic Group Chris Potter AstraZeneca: Chairman](https://reader030.fdocuments.us/reader030/viewer/2022013107/5b5877407f8b9a655d8c0ad1/html5/thumbnails/58.jpg)
58
Fluid-bed DryingSummary
Two failure modes, one of which also impacts down-stream processing
hydrolysis of the API (degradation to des-ethyl examplain)decreased tablet weight uniformity resulting from poor granule flow associated with the generation of fines.
The disintegration and dissolution properties of the examplain hydrochloride tablets are insensitive to the drying operationDesign Space established independent of scale
![Page 59: PAT and Quality by Design exemplified in a Mock P2 ...gmpeye.co.kr/gmpguidesandguidelines/quality by design... · 3 Introduction EFPIA PAT Topic Group Chris Potter AstraZeneca: Chairman](https://reader030.fdocuments.us/reader030/viewer/2022013107/5b5877407f8b9a655d8c0ad1/html5/thumbnails/59.jpg)
59
Third Review of Risk AssessmentUnit operations / Quality attributes
Dispensing (Raw Material
Properties) Granulation Drying
Blending (Magnesium
Stearate) Tableting Packaging
Dissolution
Fig 3 (Particle size API)
see 3.2.P.2.3.1. Prior knowledge No significant effect based on Formulation Development
Fig 9 Fig 9 Prior knowledge
Disintegration
Fig 3 (deduced) see 3.2.P.2.3.1. Prior knowledge No significant effect based on Formulation Development
Fig 9 & 3.2.P.2.1.1 & 3.2.P.2.2.3 (deduced)
Fig 9 & 3.2.P.2.1.1 & 3.2.P.2.2.3 (deduced)
Prior knowledge
Hardness Prior knowledge Prior knowledge Prior knowledge Fig 8 Fig 7 Prior knowledge
Assay Prior knowledge Prior knowledge Prior knowledge Prior knowledge Prior knowledge
Content uniformity Prior knowledge ???? Prior knowledge
Degradation Prior knowledge see 3.2.P.2.3.1. Prior knowledge Prior knowledge
Stability
Prior knowledge Prior knowledge Water content less than 2% based on Formulation Development
Prior knowledge Prior knowledge Prior knowledge
Appearance Prior knowledge Prior knowledge Prior knowledge Prior knowledge
Identification Based on Control Strategy
Prior knowledge Prior knowledge Prior knowledge Prior knowledge Prior knowledge
Water
Prior knowledge Prior knowledge see 3.3 Water content unchanged after FBD
Water content unchanged after FBD
Water content unchanged after FBD
Microbiology Specification of starting material
Prior knowledge Prior knowledge Prior knowledge Prior knowledge
![Page 60: PAT and Quality by Design exemplified in a Mock P2 ...gmpeye.co.kr/gmpguidesandguidelines/quality by design... · 3 Introduction EFPIA PAT Topic Group Chris Potter AstraZeneca: Chairman](https://reader030.fdocuments.us/reader030/viewer/2022013107/5b5877407f8b9a655d8c0ad1/html5/thumbnails/60.jpg)
60
Fluid-bed DryingControl Strategy
Controlling both the final water content and the time course of achieving it (the “drying trajectory”), the performance of the examplain hydrochloride tablets can be assured
![Page 61: PAT and Quality by Design exemplified in a Mock P2 ...gmpeye.co.kr/gmpguidesandguidelines/quality by design... · 3 Introduction EFPIA PAT Topic Group Chris Potter AstraZeneca: Chairman](https://reader030.fdocuments.us/reader030/viewer/2022013107/5b5877407f8b9a655d8c0ad1/html5/thumbnails/61.jpg)
61
Control StrategyDrying & Blending
The progress and end point of drying are monitored by on-line NIR and on-line laser particle size measurementsThe critical material attribute, water content of the granulate is controlled by adjusting air flow and inlet air temperature The particle size distribution is monitored by laser diffraction on-line measurementsThe end point of the drying is the range 1.5% to 2.0% water content with a target of 1.75% measured by on-line NIRThe end point of the blending is determined by on-line NIR
![Page 62: PAT and Quality by Design exemplified in a Mock P2 ...gmpeye.co.kr/gmpguidesandguidelines/quality by design... · 3 Introduction EFPIA PAT Topic Group Chris Potter AstraZeneca: Chairman](https://reader030.fdocuments.us/reader030/viewer/2022013107/5b5877407f8b9a655d8c0ad1/html5/thumbnails/62.jpg)
62
Wet granule Dry granule
Water contentParticle size
Water contentAPI Size distribution
Outlet RHOutlet Temp
Bed TempAir flowTime
Inlet Temp
NIR FBRMgranule size distribution
w ater content
Fluid Bed Drier
colour code: Red - input variables; Green - derived parameters; Blue - on-line measurements
controlled bygranulation operation
Process DevelopmentKey Process Variables for FBD
![Page 63: PAT and Quality by Design exemplified in a Mock P2 ...gmpeye.co.kr/gmpguidesandguidelines/quality by design... · 3 Introduction EFPIA PAT Topic Group Chris Potter AstraZeneca: Chairman](https://reader030.fdocuments.us/reader030/viewer/2022013107/5b5877407f8b9a655d8c0ad1/html5/thumbnails/63.jpg)
63
Dis DOE
Dis PS ConfirmatoryBatches
Dis PS Test
A Multivariate Model for Predicting Disintegration
PS = Pilot scale
Scale:
2
8
15
2 8 15Predicted
Examplain_DOE_DisintegrationDis_DOEDis_PS ICH
Obs
erve
d
Dis_PS Test
![Page 64: PAT and Quality by Design exemplified in a Mock P2 ...gmpeye.co.kr/gmpguidesandguidelines/quality by design... · 3 Introduction EFPIA PAT Topic Group Chris Potter AstraZeneca: Chairman](https://reader030.fdocuments.us/reader030/viewer/2022013107/5b5877407f8b9a655d8c0ad1/html5/thumbnails/64.jpg)
64
Control
Process control strategy
Product release strategyRTRFinal product testing
![Page 65: PAT and Quality by Design exemplified in a Mock P2 ...gmpeye.co.kr/gmpguidesandguidelines/quality by design... · 3 Introduction EFPIA PAT Topic Group Chris Potter AstraZeneca: Chairman](https://reader030.fdocuments.us/reader030/viewer/2022013107/5b5877407f8b9a655d8c0ad1/html5/thumbnails/65.jpg)
65
Control Strategy 1/2
Based on the Quality Risk Management the optimal control strategy is proposed so that all possible failures were reduced to an acceptable levelProcess controls including end point controls are established based on direct and timely measurements of relevant material attributes and relevant process parametersThe control strategy proposed ensures that the natural variability of raw materials can be manage by the process itselfThe process therefore has been adjusted to give target quality endpoints of material attributes that are relevant for the next processing steps.
![Page 66: PAT and Quality by Design exemplified in a Mock P2 ...gmpeye.co.kr/gmpguidesandguidelines/quality by design... · 3 Introduction EFPIA PAT Topic Group Chris Potter AstraZeneca: Chairman](https://reader030.fdocuments.us/reader030/viewer/2022013107/5b5877407f8b9a655d8c0ad1/html5/thumbnails/66.jpg)
66
Control Strategy 2/2
In summary the following process controls will ensure robust and consistent processes leading toconsistent end product quality
NIR for raw materials on receipt or when dispensingPower consumption for granulation end pointOn-line NIR and laser diffraction of the drying processOn-line NIR for blend uniformityCompression force control and at-line NIR during compression for:
content uniformityprediction of hardnessdisintegration and dissolution
![Page 67: PAT and Quality by Design exemplified in a Mock P2 ...gmpeye.co.kr/gmpguidesandguidelines/quality by design... · 3 Introduction EFPIA PAT Topic Group Chris Potter AstraZeneca: Chairman](https://reader030.fdocuments.us/reader030/viewer/2022013107/5b5877407f8b9a655d8c0ad1/html5/thumbnails/67.jpg)
67
Manufacturing Process- Control Strategy -
Unit OperationsAttributesControls
Content Uniformity NIR
Water Content – NIRParticle size – FBRM
Dispensation
Blending
Tableting
Blend Homogeneity-NIR
Fluidized Bed Dryer
Packaging
Identity-NIR
Granulation
Extent of Wet Massing -
Power Consumption
Air
Scale
Multivariate Model (predictsDisintegration)
Raw Materials
![Page 68: PAT and Quality by Design exemplified in a Mock P2 ...gmpeye.co.kr/gmpguidesandguidelines/quality by design... · 3 Introduction EFPIA PAT Topic Group Chris Potter AstraZeneca: Chairman](https://reader030.fdocuments.us/reader030/viewer/2022013107/5b5877407f8b9a655d8c0ad1/html5/thumbnails/68.jpg)
68
Control StrategyDispensing
Raw materials (drug substance and excipients) identification are performed by NIR applicationThe NIR spectra are also used to detect differences in physicochemical properties by correlating the NIR spectra in a multivariate way with end product quality characteristicsNormal GMP double-checking of weighing and transfers assures correct weights of materials are added.
Identity-NIR
DispensationScale
Multivariate Model (predictsDisintegration)
Raw Materials
![Page 69: PAT and Quality by Design exemplified in a Mock P2 ...gmpeye.co.kr/gmpguidesandguidelines/quality by design... · 3 Introduction EFPIA PAT Topic Group Chris Potter AstraZeneca: Chairman](https://reader030.fdocuments.us/reader030/viewer/2022013107/5b5877407f8b9a655d8c0ad1/html5/thumbnails/69.jpg)
69
Control StrategyTableting
Adjustment of the granulate feed through modern compression force feedback to control the process ensures target tablet weight and consequently content uniformityAn automated weight control and at-line NIR measurement system allows feedback to the feed control and compression force system (compression of 100% tablets) At-line NIR confirms content uniformity and can detect any unexpected segregation of the blend during compressionThe NIR also allows the monitoring of water content of the finaltabletsA multivariate model for hardness, disintegration and dissolution allows prediction of hardness, disintegration and dissolution
Packaging
Tableting Multivariate Model (predictsDisintegration)
![Page 70: PAT and Quality by Design exemplified in a Mock P2 ...gmpeye.co.kr/gmpguidesandguidelines/quality by design... · 3 Introduction EFPIA PAT Topic Group Chris Potter AstraZeneca: Chairman](https://reader030.fdocuments.us/reader030/viewer/2022013107/5b5877407f8b9a655d8c0ad1/html5/thumbnails/70.jpg)
70
Control Strategy 1/5Impact on end product quality specification
Dissolution & DisintegrationMechanistic understanding of the disintegration and dissolution of examplain tabletsExcellent understanding that no process or product formulation parameter within the established design space are critical for these quality attributes Established multivariate prediction model
Conclusion: Dissolution and disintegration of the final product will not be performed
![Page 71: PAT and Quality by Design exemplified in a Mock P2 ...gmpeye.co.kr/gmpguidesandguidelines/quality by design... · 3 Introduction EFPIA PAT Topic Group Chris Potter AstraZeneca: Chairman](https://reader030.fdocuments.us/reader030/viewer/2022013107/5b5877407f8b9a655d8c0ad1/html5/thumbnails/71.jpg)
71
Control Strategy 2/5Impact on end product quality specification
HardnessHardness is mainly influenced by wet granulation and compression forceInstrumented compression force feedback control DoE showed that disintegration not significantly influenced by the hardness of tabletsPrediction of hardness based on the correlation of NIR measurements with conventional hardness m measurements
Conclusion: Hardness is not a CQA for the present tabletsand will not be included in the drug product specification
![Page 72: PAT and Quality by Design exemplified in a Mock P2 ...gmpeye.co.kr/gmpguidesandguidelines/quality by design... · 3 Introduction EFPIA PAT Topic Group Chris Potter AstraZeneca: Chairman](https://reader030.fdocuments.us/reader030/viewer/2022013107/5b5877407f8b9a655d8c0ad1/html5/thumbnails/72.jpg)
72
Conclusion: At-line NIR measurements are basis forrelease decisions
on content uniformity and assay (Mean value)
Assay and Unit Dose Uniformity
Control Strategy 3/5Impact on end product quality specification
Mechanistic understanding of relevant unit operations and impact on variations on content uniformity and assay Extensive process controls and monitoringAdjustment of all unit operations to defined material attribute end points Defined drying trajectories to control fine particle quantitiesAt-line monitoring of content uniformity by NIR and the weight measurements
lead to reproducible results ofassay and content uniformity
![Page 73: PAT and Quality by Design exemplified in a Mock P2 ...gmpeye.co.kr/gmpguidesandguidelines/quality by design... · 3 Introduction EFPIA PAT Topic Group Chris Potter AstraZeneca: Chairman](https://reader030.fdocuments.us/reader030/viewer/2022013107/5b5877407f8b9a655d8c0ad1/html5/thumbnails/73.jpg)
73
Conclusion: Neither moisture content nor degradation product levels will be tested in finished product
Control Strategy 4/5Impact on end product quality specification
DegradationDes-ethyl examplain content at time of manufacture is influenced by:
water addition rate during granulationby the trajectory of the fluid bed drying processthe water content in resultant tablets
Hydrolysis is minimized through control of temperature
and water content of the granulateControl of drying process (other unit of operations have
no effect) influence on level of degradation
![Page 74: PAT and Quality by Design exemplified in a Mock P2 ...gmpeye.co.kr/gmpguidesandguidelines/quality by design... · 3 Introduction EFPIA PAT Topic Group Chris Potter AstraZeneca: Chairman](https://reader030.fdocuments.us/reader030/viewer/2022013107/5b5877407f8b9a655d8c0ad1/html5/thumbnails/74.jpg)
74
Conclusion:Reduce confirmatory stability testing after changes of equipment, scale or site, or other
changes ( assessed RM) up to 3 months based on QRA.
Stability
Control Strategy 5/5Impact on end product quality specification
Content of des-ethyl examplain is related to moisture content of tablets at time of manufacture and the uptake during storageBased on this underpinning science of water uptake and degradation rates:
the selection of the packaging materialthe control of storage of bulk product before packinglong term data on pilot batchessupported by long term testing of the first 3 production batches
![Page 75: PAT and Quality by Design exemplified in a Mock P2 ...gmpeye.co.kr/gmpguidesandguidelines/quality by design... · 3 Introduction EFPIA PAT Topic Group Chris Potter AstraZeneca: Chairman](https://reader030.fdocuments.us/reader030/viewer/2022013107/5b5877407f8b9a655d8c0ad1/html5/thumbnails/75.jpg)
75
Regulatory FlexibilityBased on:
Mechanistic process understandingConsequent application of Risk ManagementDevelopment and implementation of Design Space for each unit operationDerivation of the critical to control attributes
Regulatory flexibility is proposed for the following topics:Process validationScale and equipment changeSite changesReal time release
![Page 76: PAT and Quality by Design exemplified in a Mock P2 ...gmpeye.co.kr/gmpguidesandguidelines/quality by design... · 3 Introduction EFPIA PAT Topic Group Chris Potter AstraZeneca: Chairman](https://reader030.fdocuments.us/reader030/viewer/2022013107/5b5877407f8b9a655d8c0ad1/html5/thumbnails/76.jpg)
76
Conclusion: Therefore the 3 batch validation will be replaced by a continuous process verification.
Regulatory FlexibilityProcess validationAssurance is given that each process step (granulation and fluid-bed drying are examples) is routinely and reproducibly producing material for the next processing step through consequent manufacturing within established Design Spaces
Process verification in compliance with the design spaceApplication of the control strategy
![Page 77: PAT and Quality by Design exemplified in a Mock P2 ...gmpeye.co.kr/gmpguidesandguidelines/quality by design... · 3 Introduction EFPIA PAT Topic Group Chris Potter AstraZeneca: Chairman](https://reader030.fdocuments.us/reader030/viewer/2022013107/5b5877407f8b9a655d8c0ad1/html5/thumbnails/77.jpg)
77
Regulatory FlexibilityProposal for real time releaseBased on the high level of formulation and process understandingExtensive Quality Risk ManagementSophisticated control strategy including advanced on-line and real time measurements of relevant material attributes
The consistent acceptable quality of the end product is guaranteed
No additional batch wise end product testing is needed.
![Page 78: PAT and Quality by Design exemplified in a Mock P2 ...gmpeye.co.kr/gmpguidesandguidelines/quality by design... · 3 Introduction EFPIA PAT Topic Group Chris Potter AstraZeneca: Chairman](https://reader030.fdocuments.us/reader030/viewer/2022013107/5b5877407f8b9a655d8c0ad1/html5/thumbnails/78.jpg)
78
Conclusion:Changes of scale will be madeimmediately without notifying authorities
Design spaces for fluid bed drying andwet granulation establishedThese design spaces have been demonstrated to be transferable to and reproduced fordifferent process equipment within thedevelopmental workDifferent processing scales represented (1kg & 25kg)
Consequently the process will be operated withinthese design space
.
Regulatory FlexibilityScale & equipment changes
![Page 79: PAT and Quality by Design exemplified in a Mock P2 ...gmpeye.co.kr/gmpguidesandguidelines/quality by design... · 3 Introduction EFPIA PAT Topic Group Chris Potter AstraZeneca: Chairman](https://reader030.fdocuments.us/reader030/viewer/2022013107/5b5877407f8b9a655d8c0ad1/html5/thumbnails/79.jpg)
79
Conclusion: Operation within developed design space, atransfer (site A to site B)could be made immediately
without authorities being notified in advance
Regulatory FlexibilitySite changes
Site change means reproducing Design Space at other sites:with equivalent equipmentequivalent sources of raw materialsinspected GMP status of the sitewith equivalent quality systems
Conduction of full end product testing will be performed (first 3 batches)
Confirmation the validity of the process modelConfirmatory stability program for the first batches
![Page 80: PAT and Quality by Design exemplified in a Mock P2 ...gmpeye.co.kr/gmpguidesandguidelines/quality by design... · 3 Introduction EFPIA PAT Topic Group Chris Potter AstraZeneca: Chairman](https://reader030.fdocuments.us/reader030/viewer/2022013107/5b5877407f8b9a655d8c0ad1/html5/thumbnails/80.jpg)
80
Discussion
Thank your for your attention